These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10608719)

  • 1. Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease.
    Holvoet P
    Ther Apher; 1999 Nov; 3(4):287-93. PubMed ID: 10608719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative modification of low-density lipoproteins in atherothrombosis.
    Holvoet P
    Acta Cardiol; 1998; 53(5):253-60. PubMed ID: 9922802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of oxidatively modified low density lipoproteins and anti-oxidants in atherothrombosis.
    Holvoet P
    Expert Opin Investig Drugs; 1999 May; 8(5):527-44. PubMed ID: 15992113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.
    Holvoet P; Vanhaecke J; Janssens S; Van de Werf F; Collen D
    Circulation; 1998 Oct; 98(15):1487-94. PubMed ID: 9769301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entire Peroxidation Reaction System of Myeloperoxidase Correlates with Progressive Low-Density Lipoprotein Modifications via Reactive Aldehydes in Atherosclerotic Patients with Hypertension.
    Liu Q; Liu Y; Shi J; Gao M; Liu Y; Cong Y; Li Y; Wang Y; Yu M; Lu Y; Wang D; Chen S; Zheng Y; Cheng Y
    Cell Physiol Biochem; 2018; 50(4):1245-1254. PubMed ID: 30355911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.
    Requena JR; Fu MX; Ahmed MU; Jenkins AJ; Lyons TJ; Thorpe SR
    Nephrol Dial Transplant; 1996; 11 Suppl 5():48-53. PubMed ID: 9044307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Klotho ameliorates oxidized low density lipoprotein (ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways.
    Yao Y; Wang Y; Zhang Y; Liu C
    Lipids Health Dis; 2017 Apr; 16(1):77. PubMed ID: 28407763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
    Tanaga K; Bujo H; Inoue M; Mikami K; Kotani K; Takahashi K; Kanno T; Saito Y
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):662-6. PubMed ID: 11950707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis.
    Sakata N; Uesugi N; Takebayashi S; Nagai R; Jono T; Horiuchi S; Takeya M; Itabe H; Takano T; Myint T; Taniguchi N
    Cardiovasc Res; 2001 Feb; 49(2):466-75. PubMed ID: 11164857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
    Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of oxidative modifications in atherosclerosis.
    Stocker R; Keaney JF
    Physiol Rev; 2004 Oct; 84(4):1381-478. PubMed ID: 15383655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular diseases: oxidative damage and antioxidant protection.
    Zhang PY; Xu X; Li XC
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3091-6. PubMed ID: 25392110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
    Yoshida H
    Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased aldehyde-modification of collagen type IV in symptomatic plaques--a possible cause of endothelial dysfunction.
    Dunér P; Gonçalves I; Grufman H; Edsfeldt A; To F; Nitulescu M; Nilsson J; Bengtsson E
    Atherosclerosis; 2015 May; 240(1):26-32. PubMed ID: 25746374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small oxidative changes in atherogenic LDL concentrations irreversibly regulate adhesiveness of human endothelial cells: effect of the lazaroid U74500A.
    Colomé C; Martínez-González J; Vidal F; de Castellarnau C; Badimon L
    Atherosclerosis; 2000 Apr; 149(2):295-302. PubMed ID: 10729379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?
    Verhoye E; Langlois MR;
    Clin Chem Lab Med; 2009; 47(2):128-37. PubMed ID: 19099526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oxidized lipoproteins and atherogenesis].
    Jürgens G; Chen Q; Ledinski G; Kager G; Hammer A; Esterbauer H
    Acta Med Austriaca; 1993; 20(4):85-9. PubMed ID: 8237282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized-LDL and paraoxonase-1 as biomarkers of coronary artery disease in patients with sleep-disordered breathing.
    Hackenhaar FS; Martinez D; Medeiros TM; Klein C; Alabarse PV; Wainstein MV; Gonçalves SC; Benfato MS
    Curr Med Chem; 2012; 19(25):4359-66. PubMed ID: 22934769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein oxidation biomarkers in human health and disease and effects of bioactive compounds.
    Winklhofer-Roob BM; Faustmann G; Roob JM
    Free Radic Biol Med; 2017 Oct; 111():38-86. PubMed ID: 28456641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malondialdehyde-modified LDL as a marker of acute coronary syndromes.
    Holvoet P; Collen D; Van de Werf F
    JAMA; 1999 May; 281(18):1718-21. PubMed ID: 10328072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.